Wall Street is Bullish on DexCom (DXCM), Here's Why

DexCom, Inc. (NASDAQ:DXCM) is one of the Best NASDAQ Stocks to Buy with Huge Upside Potential. Wall Street is bullish on DexCom, Inc. (NASDAQ:DXCM) after the company topped revenue and EPS estimates during its fiscal second quarter of 2025. The company posted $1.16 billion in revenue, up 15.21% year-over-year and ahead of consensus by $32.49 million. In addition, the EPS of $0.48 also came in ahead of the expectations by $0.04.

Management noted that both the US and International revenue contributed to this outperformance with US segment growing 15% and the International segment growing 7% year-over-year.

Several analysts have reiterated their bullish sentiment since the release. Earlier, on August 21, Steven Silver from Argus Research initiated DexCom, Inc. (NASDAQ:DXCM) with a Buy and a $100 price target. Later on September 8, Bernstein also reiterated a Buy rating on the stock with a price target of $98. More recently, Piper Sandler reiterated a Buy rating with a price target of $100 on September 12, 2025. Overall, analysts 12-month price target points towards a 35.5% upside from current levels.

DexCom, Inc. (NASDAQ:DXCM) designs and develops continuous glucose monitoring systems to help people manage diabetes and metabolic health.

While we acknowledge the potential of DXCM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.